fingolimod has been researched along with thermozymocidin in 1 studies
| Studies (fingolimod) | Trials (fingolimod) | Recent Studies (post-2010) (fingolimod) | Studies (thermozymocidin) | Trials (thermozymocidin) | Recent Studies (post-2010) (thermozymocidin) |
|---|---|---|---|---|---|
| 65 | 0 | 51 | 267 | 1 | 148 |
| Protein | Taxonomy | fingolimod (IC50) | thermozymocidin (IC50) |
|---|---|---|---|
| Serine palmitoyltransferase 2 | Homo sapiens (human) | 0.0001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oberlies, NH; Pearce, CJ; Strader, CR | 1 |
1 review(s) available for fingolimod and thermozymocidin
| Article | Year |
|---|---|
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Topics: Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Hypocreales; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Structure-Activity Relationship; United States; United States Food and Drug Administration | 2011 |